Related Experiment Video

Updated: Jun 6, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Antibodies and Tyrosine Kinase Inhibitors in Breast Cancer Therapies

J Barth1, Christian Jackisch, Michael Untch

  • 1StiL (Study Group of Indolent Lymphomas) Central Office, Med Klin IV, Justus-Liebig-University Giessen, Offenbach, Germany.

Breast Care (Basel, Switzerland)
|December 17, 2010
PubMed

Insights

Targeted therapy offers new breast cancer treatment options. Advances include Her2/neu antibodies like trastuzumab and kinase inhibitors, with ongoing clinical trials for further approvals.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Breast cancer treatment has evolved with targeted molecular therapies.
  • Key approvals include trastuzumab (anti-Her2/neu antibody) and bevacizumab (antiangiogenic antibody).
  • Understanding carcinogenesis and tumor growth fuels new drug development.

Purpose of the Study:

  • To review the current state of targeted therapy for breast cancer.
  • To discuss potential future developments in this field.

Main Methods:

  • Literature review of recent advancements in targeted breast cancer therapy.
  • Analysis of approved drugs and ongoing clinical trials.

Main Results:

  • Trastuzumab and bevacizumab represent significant targeted treatments.
  • Kinase inhibitors are a major class of emerging molecules.
  • Several targeted therapies have gained regulatory approval.
  • Numerous clinical trials are underway for new targeted agents.

Conclusions:

  • Targeted therapy has become a cornerstone in breast cancer treatment.
  • Future developments will likely focus on novel molecular targets and combination therapies.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...